CagriSema vs Tirzepatide

Name: CagriSema vs Tirzepatide
Published: 2026-10-24

Updated Oct 24, 20267 sources

Key differences

1REDEFINE 4 (84 weeks, open label): CagriSema 2.4/2.4 mg 23.0% vs tirzepatide 15 mg 25.5% if all adhered; 20.2% vs 23.6% counting everyone. Non-inferiority was missed.
2REIMAGINE 5 (60 weeks, type 2 diabetes): CagriSema 1.0/1.0 mg 12.4% vs tirzepatide 5 mg 9.1%, superior on weight.

Facts from each record, in the same words as their own pages.

CagriSema and Tirzepatide side by side
	CagriSema	Tirzepatide
Category	Weight loss, GLP-1	GLP-1, Weight loss
Evidence	Strong human trials	Strong human trials
FDA status	In clinical trialsRegulatory	FDA approved as Mounjaro +1Regulatory
WADA	Not confirmed	Not prohibited
Half-life	Cagrilintide component: 159 to 195 hours, peaking 24 to 72 hours after a dose (phase 1b, given with semaglutide).Clinical study Semaglutide component: 145 to 165 hours, peaking 12 to 24 hours after a dose (same trial).Clinical study	About 5 days (Mounjaro label); 5 to 6 days in people with obesity or sleep apnea (Zepbound label). That is why it is dosed once a week.Regulatory
Routes	Subcutaneous injection	Subcutaneous injection
Forms	Vial (powder)	Not reported
Reported doses	0.16 to 4.5 mg (subcutaneous injection)	0.25 to 15 mg (subcutaneous injection)
Most cited frequency	Once weekly, cagrilintide and semaglutide at the same mg (2.4 mg + 2.4 mg at maintenance)	Once weekly. Step up 2.5 mg after at least 4 weeks only if needed, then hold the maintenance dose.
Vial sizes	5 mg, 10 mg, 20 mgVendor guide	10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mgCompetitor guide
Mixed vial keeps	Fridge at 2 to 8 °C, use within 30 days.Vendor guide	Keep the mixed vial in the fridge and use it within about 28 days.Competitor guide
Protocols on file	6	12

Doses shown are what sources report, labelled by origin. Not medical advice.

7 sources, each checked by date. Record updated Oct 24, 2026. Numbers are restated in our own words and labelled by where they came from.